Introduction The rVSVDG-ZEBOV-GP (Ervebo®) vaccine is both immunogenic and
protective against Ebola. However, the vaccine can cause a broad range of transient …

Background A recombinant vesicular stomatitis virus vector expressing the Zaire Ebola virus
glycoprotein (rVSVΔG-ZEBOV-GP) vaccine has been reported as safe, immunogenic, and …

The 2014–2015 Ebola epidemic affected several African countries, claiming more than
11,000 lives and leaving thousands with ongoing sequelae. Safe and effective vaccines …

Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach
to identify early innate immune correlates of antibody induction in humans receiving the …

Abstract Objectives For Ebola vaccine development, antibody response is a major endpoint
although its determinants are not well known. We aimed to review Ebola vaccine studies …

Background During the last decade Ebola virus has caused several outbreaks in Africa. The
recombinant vesicular stomatitis virus-vectored Zaire Ebola (rVSVΔG-ZEBOV-GP) vaccine …

With an emphasis on systems analyses, the VSV-EBOVAC project harnesses state-of-the-art
technologies that illuminate mechanisms behind the observed immunogenicity and …

Ebola virus disease is a severe hemorrhagic fever with a high fatality rate. We investigate
transcriptome profiles at 3 h, 1 day, and 7 days after vaccination with Ad26. ZEBOV and MVA …

Ebolavirus Disease (EVD) is a severe haemorrhagic fever that occurs in epidemic
outbreaks, with a high fatality rate and no specific therapies available. rVSVΔG-ZEBOV-GP …

Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost
impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such …